

**MISSISSIPPI DIVISION OF MEDICAID
DRUG UTILIZATION REVIEW (DUR) BOARD
MINUTES OF THE SEPTEMBER 19, 2019 MEETING**

DUR Board Members:	Dec 2018	Mar 2019	May 2019	Sep 2019
Lauren Bloodworth, PharmD	✓		✓	✓
Beverly Bryant, MD	✓	✓		✓
Rhonda Dunaway, RPh	✓	✓	✓	✓
Tanya Fitts, MD	✓	✓	✓	
Ray Montalvo, MD (Chair)	✓	✓		✓
Holly Moore, PharmD	✓		✓	✓
Janet Ricks, DO	✓	✓	✓	
Dennis Smith, RPh	✓	✓	✓	✓
Cheryl Sudduth, RPh	NA	NA	NA	✓
James Taylor, PharmD	✓	✓	✓	✓
Alan Torrey, MD	NA	NA	NA	✓
Veda Vedanarayanan, MD	✓	✓	✓	✓
TOTAL PRESENT	11*	10*	8*	10

** Total Present may not be reflected by individual members marked as present above due to members whose terms expired being removed from the list.*

Also Present:

Division of Medicaid (DOM) Staff:

Terri Kirby, RPh, CPM, Pharmacy Director; Cindy Noble, PharmD, MPH, DUR Coordinator; Carlos Latorre, MD, Medical Director; Chris Yount, MA, PMP, Staff Officer – Pharmacy; Sue Reno, RN, Program Integrity; Vanessa Banks, RN, Program Integrity; Christy Lyle, RN, Nurse Office Director of Clinical Support Services

University of Mississippi School of Pharmacy - MS-DUR Staff:

Eric Pittman, PharmD, MS-DUR Project Director; Kaustuv Bhattachaya, MS-DUR Analyst; Sushmitha Inguva, MS-DUR Analyst

Conduent Staff:

Lew Anne Snow, RN, BSN, Pharmacy Services Sr. Analyst, Mississippi Medicaid Project

Change Healthcare Staff:

Paige Clayton, PharmD, On-Site Clinical Pharmacist; Cheryl Rogers, PharmD, Mississippi PA Pharmacist; Shannon Hardwick, RPh, CPC Pharmacist

IBM Watson Health:

Mary Sawardecker, MHA, RHIA, Analytic Consultant Sr., Mississippi Medicaid Project

Alliant Health:

Catherine Brett, MD, MPH, Alliant Health Solutions' Quality Director, MS UM/QIO

Coordinated Care Organization (CCO) Staff:

Heather Odem, PharmD, Director of Pharmacy - Mississippi, UnitedHealthcare Community & State; Jenni Grantham, PharmD, Director of Pharmacy, Magnolia Health; Mike Todaro; PharmD, Vice President Pharmacy Operations, Magnolia Health; Trina Stewart, PharmD, Pharmacy Manager, Molina Healthcare; Joseph Vazhappilly, PharmD, MBA, Associate Vice President, Pharmacy Services, Molina Healthcare

Visitors:

Bryнна Clark, MPhA; Judy Clark, Consultant; Evelyn Johnson, Capital Resources; Alice Kelly Morgan, Pfizer; Beau Pender, Otsuka; Patrick Moty, Horizon Therapeutics; Melissa Sanders, UMMC FM; Peter Magargee, Sobi; Jeff Knappen, Spark; Gene Wingo, Biogen; Brooke Long, University of Mississippi (UM) Pharmacy Student; Andrea Washington, UM Pharmacy Student

Call to Order:

Dr. Ray Montalvo, Chair, called the meeting to order at 1:03pm and welcomed our new board members, Alan Torre, MD and Cheryl Sudduth, RPh.

OLD BUSINESS:

Mr. Smith moved to approve the minutes from the May 2019 DUR Board Meeting, seconded by Dr. Bloodworth and unanimously approved by the DUR Board.

Resource Utilization Review:

Dr. Pittman presented the resource utilization report for April 2019 – June 2019. No significant trends or shifts were noted for this period.

NEW BUSINESS**Update on MS-DUR Educational Interventions:**

Dr. Pittman provided an overview of all DUR mailings that occurred May 2019 - August 2019. The mailings included on-going mailings addressing concomitant prescribing of opioids and benzodiazepines, prescribing of opioids at high morphine equivalent daily doses (MEDD), and provider shopping. A one-time mailing addressing the implementation of opioid prior authorization edits was also distributed.

CCO Update on Case Management Services for Beneficiaries at High Risk of Preterm Births:

Each CCO pharmacy director/manager presented information on their respective case management services their organizations have in place for beneficiaries at risk of experiencing a preterm birth.

UnitedHealthcare (UHC) Community and State: Heather Odem, Director of Pharmacy, described UHC's Maternal Child Health Program Healthy First Steps. A maternal child health coordinator who is a MS licensed RN receives pregnant member referrals. Members are given a clinical assessment and an individualized care plan is developed. Members are followed through their pregnancies and for 2 months after delivery. A variety of assistance approaches are provided for members enrolled in this service. For 2019 to date, the average preterm delivery rate for members enrolled in Healthy First Steps is 11%, compared to the Mississippi state average of 17%.

Molina Healthcare: Trina Stewart, Pharmacy Manager, detailed Molina's Motherhood Matters Pregnancy Program. She discussed triggers that are used to identify potential beneficiaries for enrollment in the program. The program provides individualized care specific for each beneficiary's

needs including smoking cessation and substance abuse treatment. They also have a dedicated Makena Care Management Team focused on educating beneficiaries on proper administration and monitoring adherence/compliance related issues.

Magnolia Health: Jenni Grantham, Director of Pharmacy, described the process Magnolia uses to identify and contact beneficiaries who are pregnant. Case management categorizes beneficiaries and reaches out to those beneficiaries who may be candidates for Makena. Case managers open a Makena Journal for each beneficiary receiving Makena which serves to document all information related to that pregnancy. Case management works closely with beneficiaries to meet their individual needs.

Special Analysis Projects:

Utilization of the CADD List

Dr. Pittman presented the DUR Board with a report on the drugs included in the Clinician Administered Drugs and Implantable Drug Devices (CADD) List. Dr. Pittman reviewed prescribing trends related to each drug category on the CADD List. With the introduction of the CADD List effective July 1, 2018, medications across all categories of the CADD List have seen shifts in claims from medical to point of sale (POS) pharmacy claims. Atypical long-acting injectable antipsychotics have also seen a significant increase in utilization since addition to the CADD List, indicating improved access. No formal recommendations were made regarding the CADD List.

Type 2 Diabetes Management and Utilization of Metformin

Dr. Noble presented background on the impact of diabetes and changes that are currently taking place in the diabetes treatment market. Dr. Pittman presented current treatment guideline recommendations and an overview of the utilization of noninsulin diabetes treatments in MS Medicaid. Some areas highlighted in the data analysis included the number of beneficiaries without a history of a documented trial of metformin prior to initiating another diabetes agent, the formulation of metformin used in those who had a documented trial of metformin, and those patients prescribed diabetes agents without documentation of a diabetes diagnosis. The DUR Board held a robust discussion around issues related to diabetes treatment.

At the conclusion of the discussion, the DUR Board did not make a formal recommendation regarding clinical edits related to diabetes treatment at this time. The Board felt it would be appropriate to wait until updated diabetes guidelines are released at the beginning of 2020 before making any formal recommendations. Dr. Bryant, with a second from Dr. Torrey, made a motion for DOM to develop a short educational bulletin promoting the use of metformin, describing benefits of extended release formulations over the immediate release formulations, and listing formulations of metformin that are preferred under the Universal Preferred Drug List (UPDL). The DUR Board unanimously approved the motion. Dr. Latorre volunteered to work with Dr. Pittman to develop this bulletin and distribute it to state medical societies for physicians, nurse practitioners, and physician assistants. Mr. Smith also encouraged DOM to explore opportunities for pharmacists to be able to intervene at POS to change metformin from immediate release to extended release formulations.

Synagis Update

Dr. Noble presented a background for the discussion on Synagis. Dr. Pittman provided the Board with an overview of 2018-2019 RSV season and utilization of Synagis.

Influenza Update

Dr. Pittman presented the Board with an overview of the 2018-2019 influenza season and influenza treatment patterns during this 2018-2019 season in Mississippi Medicaid. CDC’s vaccination recommendations for the 2019-2020 season were provided. Following discussion from the Board, Dr. Taylor made a motion, seconded by Mr. Smith, supporting the removal of the influenza vaccine from counting toward the prescription drug limit of a beneficiary. The DUR Board unanimously approved the motion.

CMS Child Core Set Update

Dr. Pittman presented a brief description of a CMS Child Core Set report DOM submitted regarding the use of multiple concurrent antipsychotics in children and adolescents.

Opioid Initiative Update:

Ms. Kirby gave a brief update to the DUR Board on the implementation of DOM’s opioid initiatives.

FDA Drug Safety Updates:

Dr. Pittman presented FDA drug safety communications for May 2019 – August 2019.

Pharmacy Program Update:

Ms. Kirby informed the Board of pharmacy stakeholder meetings that are currently being held. DOM has been hosting pharmacy stakeholder meetings throughout 2019 for the purpose of collaborating with pharmacists regarding cognitive services they can provide. The third meeting will be held on September 25, 2019. Ms. Kirby, along with Drew Snyder, recently visited Tyson’s Drugs in Holly Springs, MS. She discussed ongoing efforts to involve pharmacists in the patient care process and reimburse pharmacists for patient care management (cognitive) services they provide.

Miscellaneous:

2020 Proposed Meeting Dates/Times

March 19, 2020

June 11, 2020

September 17, 2020

December 3, 2020

**Meeting times will remain at 1 pm for the next year.*

New Co-Chair:

Dr. Bloodworth volunteered to serve as Co-Chair for 2020. She was unanimously approved.

Next Meeting Information:

Dr. Taylor announced that the next meeting of the DUR Board will take place on December 5, 2019 at 1pm.

The meeting adjourned at 3:20 pm.

Submitted,

Eric Pittman, PharmD
Evidence-Based DUR Initiative, MS-DUR

Meeting Location: Woolfolk Building, 501 North West Street, Conference Room 145, Jackson, MS 39201

Contact Information: Pharmacy Bureau:
Chris Yount, 601-359-5253; Christopher.yount@medicaid.ms.gov, or
Jessica Tyson, 601-359-5253; Jessica.Tyson@medicaid.ms.gov

Notice details:

State Agency: MS Division of Medicaid

Public Body: Drug Utilization Board (DUR) Meeting

Subject: Quarterly Meeting

Date and Time: September 19, 2019 at 1PM

Description: The Mississippi Division of Medicaid's Drug Utilization Review (DUR) Board is a quality assurance body which seeks to assure appropriate drug therapy to include optimal beneficiary outcomes and appropriate education for physicians, pharmacists, and the beneficiary. The Drug Utilization Review (DUR) Board is composed of twelve participating physicians and pharmacists who are active MS Medicaid providers and in good standing with their representative organizations.

The Board reviews utilization of drug therapy and evaluates the long-term success of the treatments.

The Drug Utilization Review (DUR) Board meets quarterly.



NOTICE DETAILS

NOTICE DETAILS

State Agency: Division of Medicaid

Public Body: Division of Medicaid

Title: Drug Utilization Review Board

Subject: Quarterly Meeting

Date and Time: 9/19/2019 1:00:00 PM

Description:

Division of Medicaid Quarterly Drug Utilization Review Board Meeting.

MEETING LOCATION

501 North West Street Conf Room 145
Jackson MS 39201

[Map this!](#)

CONTACT INFORMATION

DOM Pharmacy Bureau
6013595253
dompharmacybureau@medicaid.ms.gov

DOWNLOAD ATTACHMENTS

[DFA Meeting notification May Sept 2019.docx](#)
Added 3/7/2019

SUBSCRIPTION OPTIONS

Subscription options will send you alerts regarding future notices posted by this public body.

[RSS](#)